January 8, 2018
The federal lawsuit over Axiron, a prescription treatment for low testosterone in men, was settled last week with Axiron manufacturer Eli Lilly, who agreed to pay financial settlements to all claimants injured by their testosterone medications.
“On today’s date, December 21, 2017,” the Court’s Official Statement reads, “the Court has been advised by…Eli Lilly and Company, that they have reached a global settlement, including all filed cases.”
The total amount of the settlement reached among the thousands of cases against Eli Lilly has not yet been disclosed, however, previous cases against a similar popular treatment AndroGel awarded as much as $150,000,000 in cases linking the testosterone treatment to heart attack, stroke and death.
If you have been injured by blood clots, deep vein thrombosis, pulmonary embolism, heart attack, stroke, or any other conditions that you believe may have been caused by taking a prescription testosterone treatment, please contact us immediately to see if you can qualify for monetary compensation related to this settlement.
Although testosterone treatments were approved by the FDA for treatment of hypogonadism, or failure of the testes to function properly, prescription testosterone medications were being prescribed for treatment in men who naturally have lower than normal levels of the male hormone based on their age and health. These medications, however, were never proven safe and effective for improving the effects caused by age-related testosterone deficiencies. These medications must be prescribed by a doctor and may include: Androderm, Androgel, Bio T Gel, Delatestryl, Depo Testosterone, Fortesta, Striant, Testim and Testopel.
After a slew of adverse reactions were reported to the FDA by users, in the spring of 2015, the manufacturers were ordered to update their warning labels with a statement to patients that usage may increased risk of heart attacks and stroke, and that to be clear that these such medications are only approved to be prescribed to men who suffer from hypogonadism.
Only a few months later, the FDA added to their demands that testosterone medication warning labels should include a general warning about the increased risks of blood clots, venous thromboembolism, deep vein thrombosis (DVT) and pulmonary embolism (PE).